NCL

Nucleolin · P19338 · NCL on Sugi Atlas →

0 patent compounds predicted against NCL, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NCL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) PHASE3COMPLETED
Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine PHASE2COMPLETED
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis PHASE1COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders PHASE1RECRUITING
Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database nanRECRUITING
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis nanRECRUITING
Correlation of Polymorphisms of Lipoprotein Lipase (LpL) and Apolipoprotein E (Apo E) With Lipid Profile of Children With Acute Lymphoblastic Eukaemia During Therapy With L - Asparaginase. nanUNKNOWN
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia nanCOMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma nanCOMPLETED
Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae nanACTIVE_NOT_RECRUITING
Italian NCL Registry: a Registry for NCL as an Integration Tool for Future Therapeutic Strategies nanRECRUITING
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults nanCOMPLETED
PCM1-JAK2 in Therapy Related Neoplasms nanUNKNOWN
Genetics of Neonatal Encephalopathy and Related Disorders nanRECRUITING
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants. nanCOMPLETED
Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification nanCOMPLETED
Prenatal Genetic Diagnosis by Genomic Sequencing nanCOMPLETED
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia nanRECRUITING
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Neuroblastoma Precision Trial nanACTIVE_NOT_RECRUITING
Nephrotic Syndrome Study Network nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) nanCOMPLETED
Multi-Dimensional Genomic Dissection of Ring Chromosome 14 Syndrome nanACTIVE_NOT_RECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) nanRECRUITING
Study of DNA in Blood Samples From Patients With Neuroblastoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NCL binder may also engage these)

ProteinNameSimilarity
Q4R4J7 1.000 Q4R4J7 →
Q5RF26 1.000 Q5RF26 →
P09405 1.000 P09405 →
P08199 1.000 P08199 →
P13383 0.999 P13383 →
P20397 0.994 P20397 →
P15771 0.993 P15771 →
Q9FVQ1 0.987 Q9FVQ1 →
Q6Z1C0 0.981 Q6Z1C0 →
Q7XTT4 0.978 Q7XTT4 →
P27476 0.975 P27476 →
P41891 0.971 P41891 →
Q1PEP5 0.965 Q1PEP5 →
P27347 0.963 P27347 →
Q08473 0.960 Q08473 →
P40621 0.959 P40621 →
Q56WH4 0.959 Q56WH4 →
Q9FVE6 0.956 Q9FVE6 →
A0A1L9X986 0.953 A0A1L9X986 →
O45181 0.953 O45181 →
P0C1J6 0.952 P0C1J6 →
Q9ASP6 0.952 Q9ASP6 →
Q05783 0.952 Q05783 →
Q26486 0.952 Q26486 →
A2Q848 0.951 A2Q848 →
Q8LJS2 0.951 Q8LJS2 →
Q0CR95 0.950 Q0CR95 →
Q06943 0.950 Q06943 →
Q9M4U4 0.950 Q9M4U4 →
Q6C2Q7 0.949 Q6C2Q7 →